Sign in
  1. Home
  2. Companies
  3. Neogen Corporation
  4. Financial Statements
  5. Income Statement
Neogen Corporation logo
Neogen Corporation NEOG
$ 13.57 2.72%
report update icon

Quarterly report 2026-Q3
added 07-30-2026

Neogen Corporation Income Statement 2026-2009 | NEOG

Brief overview of income trends at Neogen Corporation

This overview is based on financial performance over the past five years. Revenue reported by Neogen Corporation was 418 million dollars at the beginning of the period and 895 million dollars at the end. Across the full period, sales moved by +113.9%; the average annual rate was 16.4%. Top-line growth remained consistently strong over the period.

At the gross-profit level, the result moved from $196 million to $421 million, a change of +114.7%. The relationship between revenue and direct costs remained stable. Gross profit as a share of revenue changed from 46.9% to 47.1%. The gross margin stayed within a similar range.

EBITDA was $85.9 million at the beginning and −$942 million at the end of the period (−1195.8%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 20.5% at the start and −105.2% at the end. Operating return per unit of revenue declined.

The final result was 59.5 million dollars initially and −1.1 billion dollars in the final year. Profit turned into a loss, the most concerning signal in the results.

Market capitalization changed from 4.2 billion dollars to 1 billion dollars (−75.8%). Financial performance is stronger than the share-price trend.

What the figures show

Signs of deterioration dominate the five-year picture. The positive side is supported by steady gross profitability and sales growth. The overall view is constrained by pressure on operating profitability, limited operating profitability and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Neogen Corporation

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

 2.51 B 1.02 B 3.81 B 4.5 B 2.45 B 3.88 B 4.2 B 3.24 B 4.15 B 2.64 B 2.11 B 1.76 B 1.49 B 1.34 B 1.09 B 1.04 B 147 M -

Shares

 218 M 217 M 216 M 189 M 108 M 106 M 105 M 104 M 103 M 102 M 100 M 99 M 98 M 96.2 M 94.5 M 92 M 22.4 M -

Historical Prices

 11.5 4.7 17.6 23.8 22.8 36.5 40.4 33.6 30.5 29.5 24.8 19.6 17.3 15.8 11.6 8.14 6.53 3.69

Net Income

 -7.9 M -1.09 B -9.4 M -22.9 M 48.3 M 60.9 M 59.5 M 60.2 M 63.1 M 43.8 M 36.6 M 33.5 M 28.2 M 27.2 M 22.5 M 22.8 M 6.11 M -

Revenue

 870 M 895 M 924 M 822 M 527 M 468 M 418 M 414 M 402 M 362 M 321 M 283 M 247 M 208 M 184 M 173 M - -

Cost of Revenue

 462 M 473 M 460 M 416 M 284 M 253 M 222 M 222 M 212 M 190 M 168 M 143 M 125 M 98 M 91.6 M 84.9 M - -

Gross Profit

 408 M 421 M 464 M 406 M 243 M 215 M 196 M 192 M 190 M 172 M 153 M 140 M 123 M 109 M 92.4 M 87.8 M 22.5 M -

Operating Income

 -21.6 M -1.06 B 58.6 M 37.5 M 58.6 M 74.2 M 67.5 M 68.1 M 70.2 M 64.9 M 56.4 M 53.1 M 43.4 M 40.7 M 33.7 M 35.8 M 26.9 M -

Interest Expense

 24.1 M 38.1 M -5.9 M 27.3 M 322 K -515 K -1.21 M 32 K 1.08 M 719 K -1.41 M -1.12 M -744 K -59 K -490 K -265 K 180 K -

EBITDA

 94.7 M -942 M 175 M 126 M 82.3 M 95.2 M 85.9 M 85.7 M 87.3 M 79.6 M 68.9 M 63.8 M 52.6 M 48.1 M 39.9 M 41.2 M 31.3 M -

Operating Expenses

 430 M 1.48 B 405 M 368 M 184 M 141 M 129 M 124 M 120 M 107 M 96.7 M 86.6 M 79.2 M 68.8 M 58.7 M 52 M 46.1 M -

General and Administrative Expenses

 245 M 218 M 200 M 201 M 82.7 M 51.2 M 44.3 M 40.8 M 38.3 M 34.2 M 29.2 M 25.2 M 24.4 M 20.2 M 17 M 15.1 M 13.5 M -

All numbers in USD currency

Quarterly Income Statement Neogen Corporation

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 218 M 217 M 218 M 217 M 217 M 217 M 217 M 217 M 217 M 217 M 217 M 216 M 216 M 216 M 216 M 216 M 108 M 108 M 108 M 108 M 107 M 108 M 107 M 106 M 106 M 53.1 M 52.8 M 52.6 M 52.3 M 52.6 M 52.3 M 52 M 51.8 M 52 M 51.8 M 51.3 M 50.9 M 51.3 M 38.2 M 50.4 M 37.6 M 37.8 M 37.6 M 37.4 M 37.2 M 37.4 M 37 M 36.9 M 36.8 M 36.9 M 36.8 M 36.5 M 36.2 M 36.5 M 24.1 M 35.7 M 23.7 M 23.8 M 23.7 M 23.4 M 23.3 M 23.4 M 23.3 M

Net Income

 -17 M -15.9 M -17 M -15.9 M 36.3 M - -10.9 M -456 M -12.6 M - -2.02 M -3.49 M 1.5 M - 8.19 M -41.8 M 5.21 M -36.6 M 5.44 M 10.8 M 17.1 M 27.9 M 13.4 M 15.9 M 15.9 M 15.9 M 12.2 M 16.3 M 14.7 M 16.3 M 14.7 M 16.1 M 15.2 M 16.1 M 15.2 M 17.1 M 11.9 M 17.1 M 11.9 M 11.2 M 9.88 M 11.2 M 9.88 M 9.14 M 9.29 M 9.07 M 9.32 M 7.83 M 8.91 M 7.81 M 8.88 M 6.21 M 7.84 M 6.21 M 7.84 M 6.79 M 6.71 M 6.79 M 6.71 M 5.24 M 6 M 5.24 M 6 M

Revenue

 211 M 225 M 211 M 225 M 209 M - 221 M 231 M 217 M - 229 M 230 M 229 M - 218 M 230 M 132 M 362 M 128 M 131 M 128 M 259 M 117 M 115 M 109 M 115 M 99.9 M 108 M 101 M 108 M 101 M 107 M 99.6 M 107 M 95.9 M 102 M 95.3 M 197 M 88.4 M 90.7 M 83.6 M 90.7 M 83.6 M 79.6 M 74.9 M 79.6 M 74.9 M 68.5 M 67.6 M 68.5 M 67.6 M 59.6 M 58.5 M 59.6 M 58.5 M 50.7 M 49.7 M 50.7 M 49.7 M 44.9 M 45.7 M 44.9 M 45.7 M

Cost of Revenue

 112 M 118 M 112 M 118 M 114 M - 111 M 118 M 112 M - 112 M 113 M 112 M - 110 M 117 M 70.1 M 188 M 70.8 M 69.9 M 68.3 M 138 M 62.9 M 61.8 M 59 M 61.8 M 54.5 M 56.8 M 53.2 M 56.8 M 53.2 M 57.1 M 52.9 M 57.1 M 50.4 M 52.5 M 49.4 M 102 M 47.5 M 47.1 M 43.2 M 47.1 M 43.2 M 41.4 M 37.1 M 41.4 M 34.7 M 34.2 M 33.5 M 34.2 M 33.5 M 30.1 M 28.2 M 30.1 M 28.2 M 23.4 M 23.2 M - - - - - -

Gross Profit

 99 M 107 M 99 M 107 M 95 M - 110 M 113 M 105 M - 117 M 117 M 117 M - 108 M 113 M 62.3 M 175 M 57.4 M 60.6 M 60 M 121 M 53.8 M 53.2 M 50.3 M 53.2 M 45.3 M 51 M 48.2 M 51 M 48.2 M 50 M 46.7 M 50 M 46.7 M 48.2 M 44.9 M 49.3 M 45.9 M 43.6 M 40.5 M 43.6 M 40.5 M 38.2 M 37.8 M 38.2 M 37.8 M 34.2 M 34.1 M 34.2 M 34.1 M 29.5 M 30.4 M 29.5 M 30.4 M 27.3 M 26.5 M 27.3 M 26.5 M 22.7 M 23 M 22.7 M 23 M

Operating Income

 -3.3 M -5.38 M -3.3 M -5.38 M -16.1 M - 5.4 M -457 M 2.26 M - 12 M 14.5 M 19.1 M - 15.7 M -7.66 M 6.06 M -1.59 M 6.38 M 12.5 M 21.7 M 34.2 M 15.8 M 19.2 M 18.9 M 19.2 M 13 M 18.3 M 16.3 M 18.3 M 16.3 M 18.2 M 16.5 M 18.2 M 16.5 M 18 M 16.4 M 18 M 16.4 M 16.9 M 14.7 M 16.9 M 14.7 M 14.6 M 14.9 M 14.6 M 12.2 M 12.9 M 13.4 M 12.9 M 13.4 M 9.69 M 12.4 M 9.69 M 12.4 M 10.5 M 10.3 M 10.5 M 10.3 M 8.14 M 9.35 M 8.14 M 9.35 M

Interest Expense

 -3.1 M -731 K -3.1 M -731 K -967 K - 1.9 M -1.72 M -244 K - -1.17 M -2.04 M -806 K - 9.06 M 8.33 M -372 K 8.5 M -48 K 235 K -221 K 14 K -91 K -465 K 193 K -465 K -393 K -317 K -122 K -317 K -122 K 427 K -269 K 427 K -269 K 626 K 443 K 626 K 443 K -377 K 369 K -377 K 369 K -471 K -524 K -471 K -508 K -64 K -16 K -64 K -16 K 11 K -552 K 11 K -552 K 75 K 47 K 75 K 47 K -40 K -33 K -32 K -68 K

EBITDA

 83.6 M 52.6 M - - 13 M - - - 32.1 M - 35.7 M 38.2 M 47.9 M - 38.6 M 15 M 11.8 M 30.9 M 8.98 M 14.9 M 27.4 M 45.7 M 15.8 M 19.2 M 23.6 M 28.8 M 13 M 18.3 M 20.7 M 27.3 M 20.7 M 18.2 M 20.8 M 26.8 M 20.8 M 18 M 20.4 M 26.3 M 20.4 M 16.9 M 18.2 M 23.9 M 18.2 M 14.6 M 17.6 M 20.3 M 12.2 M 12.9 M 16 M 18.1 M 16 M 9.69 M 14.4 M 13.9 M 14.4 M 10.5 M 12 M 13.8 M 12 M 8.14 M 10.7 M 11.1 M 10.7 M

Operating Expenses

 102 M 112 M 102 M 112 M 111 M - 105 M 571 M 103 M - 105 M 102 M 97.6 M - 92.3 M 120 M 56.2 M 176 M 51 M 48.1 M 38.3 M 86.4 M 38.1 M 34 M 31.4 M 34 M 32.3 M 32.8 M 31.9 M 32.8 M 31.9 M 31.8 M 30.2 M 31.8 M 30.2 M 30.2 M 28.5 M 31.3 M 29.4 M 26.7 M 25.7 M 26.7 M 25.7 M 23.6 M 22.9 M 23.6 M 21.5 M 21.3 M 20.6 M 21.3 M 20.6 M 19.8 M 17.9 M 19.8 M 17.9 M 16.8 M 16.2 M 16.8 M 16.2 M 14.5 M 13.6 M 14.5 M 13.6 M

General and Administrative Expenses

 60.3 M 65.2 M 60.3 M 65.2 M 60.9 M - 55.8 M 57.8 M 51.7 M - 52.1 M 51.7 M 45.1 M - 46.4 M 77 M 27.9 M 105 M 25 M 22.6 M 13.4 M 36 M 15.1 M 12.2 M 11 M 12.2 M 10.8 M 11 M 10.7 M 11 M 10.7 M 10.1 M 10.2 M 10.1 M 10.2 M 10.5 M 9.32 M 10.5 M 9.32 M 8.28 M 8.26 M 8.28 M 8.26 M 6.79 M 6.75 M 6.79 M 6.52 M 6.09 M 6.01 M 6.09 M 6.01 M 6.28 M 5.54 M 6.28 M 5.54 M 4.9 M 4.48 M 4.9 M 4.48 M 4.17 M 4.01 M 4.17 M 4.01 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Neogen Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
CareDx, Inc CareDx, Inc
CDNA
 		$ 54.31 0.32 % $ 2.89 B usaUSA
Celcuity Celcuity
CELC
 		$ 79.99 0.12 % $ 3.74 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
 		$ 1.1 1.85 % $ 1.46 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
 		$ 34.88 0.09 % $ 1.01 B usaUSA
Danaher Corporation Danaher Corporation
DHR
 		$ 221.56 0.21 % $ 158 B usaUSA
DexCom DexCom
DXCM
 		$ 87.73 0.21 % $ 34.2 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
 		$ 21.27 0.51 % $ 655 M usaUSA
Guardant Health Guardant Health
GH
 		$ 176.31 0.27 % $ 22.1 B usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
 		$ 163.9 0.2 % $ 12.9 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
 		$ 522.02 0.1 % $ 42 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
 		$ 267.86 0.41 % $ 46 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 2.75 3.33 % $ 89.2 K usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
 		$ 303.98 0.09 % $ 25.3 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
 		$ 99.97 0.01 % $ 6.75 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
 		$ 617.15 0.23 % $ 17.8 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
 		$ 1 492.34 0.11 % $ 30.8 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
 		$ 4.01 0.62 % $ 371 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
 		$ 6.5 4.33 % $ 5.12 M usaUSA
NeoGenomics NeoGenomics
NEO
 		$ 18.36 0.03 % $ 2.35 B usaUSA
Natera Natera
NTRA
 		$ 390.79 0.41 % $ 53.4 B usaUSA
Biomerica Biomerica
BMRA
 		$ 2.61 0.36 % $ 7.61 M usaUSA
OPKO Health OPKO Health
OPK
 		$ 1.7 0.29 % $ 1.28 B usaUSA
RadNet RadNet
RDNT
 		$ 73.21 0.11 % $ 5.5 B usaUSA
Sotera Health Company Sotera Health Company
SHC
 		$ 18.29 0.45 % $ 5.19 B usaUSA
Neuronetics Neuronetics
STIM
 		$ 2.88 0.21 % $ 190 M usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
 		$ 7.01 0.68 % $ 2.52 B irlandaIrlanda
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
 		$ 158.47 0.93 % $ 9.48 B usaUSA
Biodesix Biodesix
BDSX
 		$ 29.29 4.05 % $ 221 M usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
 		$ 0.25 2.99 % $ 31.4 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
 		$ 420.57 0.52 % $ 25 B usaUSA
Exagen Exagen
XGN
 		$ 8.55 1.39 % $ 184 M usaUSA
Syneos Health Syneos Health
SYNH
 		- - $ 4.46 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
 		- 5.66 % $ 22.7 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
Quotient Limited Quotient Limited
QTNT
 		- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
 		- -39.35 % $ 313 K usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
 		- - $ 1.49 B usaUSA
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
 		$ 1.7 0.55 % $ 9.26 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
 		$ 15.08 11.68 % $ 162 M chinaChina
Bioventus Bioventus
BVS
 		$ 13.61 2.55 % $ 907 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
 		$ 13.45 0.88 % $ 457 M israelIsrael